Primary Progression-Free Survival Analysis (Stratified,
ITT Population)
Analysis based upon Kaplan
–
Meier approach including stratification factors from IXRS. HR from a stratified Cox proportional hazards model including stratification factors from IXRS.
Median time of follow-up: 31 months. CI, confidence interval; HR, hazard ratio.
Pertuzumab +
Trastuzumab + AI
(n = 129)
Trastuzumab + AI
(n = 129)
Events, n
(%)
74 (57.4)
92 (71.3)
Median,
months
18.89
15.80
(95% CI)
(14.09, 27.66)
(11.04, 18.56)
∆,
months
3.09
HR (95%
CI)
0.65 (0.48, 0.89)
p-value
0.0070
12
9
12
3
12
1
11
6
11
4
10
7
10
2
91 89 84 81 77 74 71 69 65 62 58 57 56 55 53 48 46 43 39 37 36 33 28 28 26 21 16 13 13 12 10 7 5 4 3 1 1 0
12
9
12
2
11
6
10
8
10
4
93 90 81 80 75 73 67 64 61 60 56 54 47 47 39 39 36 33 32 29 26 26 23 18 15 14 12 10 9 8 6 5 3 2 2 1 1 1 1 0
N at risk
Months
Event-free Probability (%)
44
43
42
41
40
39
38
37
36
35
34
33
32
31
30
29
28
27
26
25
24
23
22
21
20
19
18
17
16
15
14
13
12
11
10
9 8 7 6 5 4 3 2 1 0
100
90
80
70
60
50
40
30
20
10
0
Median
Pertuzumab + Trastuzumab + AI
Trastuzumab + AI
N 258
30% prior trastuz
Visceral 68 to 63%
